Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Abstract
Purpose: DNA topoisomerase inhibitors are commonly used for treating small-cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single-nucleotide polymorphisms (SNP) are associated with overall survival among SCLC patients.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 14, 2017
- Source ID
- 10.1158/1078-0432.ccr-17-1401
Entities
People
- Adonina Tardón
- Christopher I Amos
- Chu Chen
- David C. Christiani
- Eric B. Haura
- Gary E. Goodman
- Geoffrey Liu
- Grainne M. O'kane
- John K. Field
- Kazushi Yoshida
- Kouya Shiraishi
- Lori C. Sakoda
- Maria Teresa Landi
- Matthew B. Schabath
- Michael P.a. Davies
- Michael W. Marcus
- Noel S. Weiss
- Pawadee Lohavanichbutr
- Ping Yang
- Rayjean J Hung
- Ruyang Zhang
- Stacey A Slone
- Susanne M Arnold
- Takashi Kohno
- Xuchen Zong
- Yi Liu
Organizations
- American Cancer Society
- Canadian Cancer Society Research Institute
- Fred Hutchinson Cancer Center
- Geisel School of Medicine
- H. Lee Moffitt Cancer Center & Research Institute
- Harvard T.H. Chan School of Public Health
- Mayo Clinic
- National Cancer Institute
- National Cancer Research Institute
- National Institutes of Health
- Sinai Health System
- United States Department of Defense
- University of Kentucky
- University of Liverpool
- University of Oviedo
- University of Toronto
- University of Washington